Screening for anal cancer in women with vulvar lesions

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to screen women over the age of 40 who have high-grade vulvar dysplasia or vulvar cancer for anal cancer, which currently lacks established screening protocols. Participants will undergo anal Pap smears and, if abnormalities are detected, high-resolution anoscopy for further evaluation and treatment. The study is based on the premise that women with gynecological lesions are at increased risk for anal lesions and cancer. By identifying and treating anal cancer early, the study seeks to improve patient outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Women age ≥ 40
* Previous diagnosis of VIN 2/3 or vulvar

Exclusion Criteria:

* Women with a previous diagnosis of cancer aside from basal cell carcinoma of the skin, cervical cancer, or vulvar cancer
* Women who are HIV positive
* Women currently taking immunosuppressant medication
* Women who have had a previous hysterectomy

Where it's running

• Odette Cancer Centre
  Toronto, Ontario, Canada Recruiting

Study contacts

• Principal investigator: Danielle Vicus, MD — Odette Cancer Centre
• Study coordinator: Nithla Mohanathas, BSc
• Email: nithla.mohanathas@sunnybrook.ca
• Phone: 4164805000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• E7 T-cell therapy for advanced HPV-related cancers

  This study is testing a new treatment using specially modified immune cells to see if it can help people with advanced cancers linked to HPV feel better and live longer.

  Recruiting at 2 sites Phase 1/2 Rutgers, The State University of New Jersey · New Brunswick, New Jersey and 1 other locations · NCT05639972

• Testing trastuzumab deruxtecan (T‑DxD) for HER2‑positive advanced solid tumors

  This will test whether trastuzumab deruxtecan (T‑DxD) helps adults in the US with HER2‑positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have had prior systemic treatment and have no satisfactory alternative options.

  Recruiting at 18 sites AstraZeneca · Birmingham, Alabama and 17 other locations · NCT07124000

• Immunotherapy using E7 TCR-T cells for HPV-related cancers

  This study is testing a new immunotherapy using E7 TCR-T cells to see if it can help people with advanced HPV-related cancers like cervical and throat cancer feel better and improve their health.

  Recruiting at 3 sites Phase 2 Rutgers, The State University of New Jersey · Bethesda, Maryland and 2 other locations · NCT05686226

• Finding HPV DNA in the blood of people with anal or cervical cancer.

  This study will test whether a blood test can find HPV DNA in people with HPV-related anal or cervical cancer before, during, and after radiation treatment.

  Recruiting at 2 sites University of Chicago · Chicago, Illinois and 1 other locations · NCT04857528

• Radiotherapy for gynecologic cancer with up to 10 metastatic sites

  This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.

  Recruiting Affidea Nu-med Center of Oncological DIagnostics and Therapy · Zamość · NCT07883798

• Irreversible Electroporation for Recurrent Pelvic Tumors

  This study tests whether using irreversible electroporation (IRE) is safe and helps control recurrent pelvic tumors in adults who can’t have other local treatments.

  Recruiting Amsterdam UMC, location VUmc · Amsterdam, North Holland · NCT07782164

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.